Akari Therapeutics (AKTX) Retained Earnings (2011 - 2026)
Akari Therapeutics' (AKTX) quarterly Retained Earnings came in at -$279.0 million in Q1 2026, down 11.16% year-on-year from -$314.0 million in Q1 2025, and down 35577.75% quarter-over-quarter from -$782000.0 in Q4 2025.
Akari Therapeutics (AKTX) Retained Earnings (2011 - 2026) Analysis & Trends
Akari Therapeutics has disclosed Retained Earnings across 16 years of filings, most recently posting -$279.0 million for Q1 2026.
- Retained Earnings for Q1 2026 came in at -$279.0 million, down 11.16% year-over-year; the trailing twelve-month figure through Mar 2026 was -$279.0 million (down 11.16% YoY), and the FY2025 annual result was -$782000.0, up 99.68% from the prior year.
- Retained Earnings came in at -$279.0 million for Q1 2026 at Akari Therapeutics, down from -$782000.0 in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of -$749000.0 in Q2 2024 to a low of -$279.0 million in Q1 2026.
- The 5-year median for Retained Earnings is -$243.5 million (2024), against an average of -$201.1 million.
- Across the five-year window, Retained Earnings sank 40097.09% in 2022 and jumped 99.68% in 2025, its largest moves.
- Akari Therapeutics' Retained Earnings stood at -$217.5 million in 2022, then declined by 4.6% to -$227.5 million in 2023, then dropped by 8.7% to -$247.3 million in 2024, then surged by 99.68% to -$782000.0 in 2025, then slumped by 35577.75% to -$279.0 million in 2026.
- The last three Retained Earnings figures came in at -$279.0 million (Q1 2026), -$782000.0 (Q4 2025), and -$259.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | -153.89 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -211.85 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.00 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 130.89 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -279.00 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.88 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -838.07 Mn |
| 10 | Regeneron Pharmaceuticals | 63.43 Bn | 54.67 Bn | 3.31 Bn | 36.42 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -279.00 Mn |
| Dec 31, 2025 | -782,000.00 |
| Sep 30, 2025 | -259.30 Mn |
| Jun 30, 2025 | -252.90 Mn |
| Mar 31, 2025 | -251.00 Mn |
| Dec 31, 2024 | -247.25 Mn |
| Sep 30, 2024 | -243.48 Mn |
| Jun 30, 2024 | -749,000.00 |
| Mar 31, 2024 | -233.00 Mn |
| Dec 31, 2023 | -227.46 Mn |
| Dec 31, 2022 | -217.45 Mn |
| Dec 31, 2021 | -540,967.00 |
| Dec 31, 2020 | -648,065.00 |
| Sep 30, 2020 | -175.47 Mn |
| Jun 30, 2020 | -617,622.00 |
| Mar 31, 2020 | -571,585.00 |
| Dec 31, 2019 | -348,860.00 |
| Sep 30, 2019 | -157.37 Mn |
| Jun 30, 2019 | -154.49 Mn |
| Mar 31, 2019 | -245,258.00 |